James Hardie's stronger foundation
With asbestos liabilities looking under control, James Hardie is set to benefit from the continuing US housing recovery.
STW doesn't ad up
This marketing company is changing strategy but argues that dividend cuts and capital raisings are off the table. Jon Mills investigates.
Time to sell Fisher & Paykel Healthcare
F&P Healthcare is a good business but the current share price is just too high.
Fisher & Paykel Healthcare: Result 2015
F&P Healthcare has produced another sound result, but don't confuse a good company with a good investment.
South32 upgraded to Buy
With a volatile share price since listing, Gaurav Sodhi explains why South32 is a Buy.
SomnoMed sets new targets
With growing acceptance in Europe, SomnoMed's sales growth continues to impress. But don't expect free cash flow any time soon.
MG Unit Trust: the poor man's Murray Goulburn?
The MG Unit Trust will let you share in the performance of Murray Goulburn. But it's dairy farmers who will call the shots.
Correction: Soul Pattinson
We made two mistakes in our last Soul Patts update. Fortunately, they largely offset each other.
Medibank's slippery slope
Australia's largest private health insurer faces plenty of headwinds, but it's also better value.
Ainsworth warns on sales
Despite now forecasting a 2% fall in revenue, Ainsworth expects 2015 profit to be similar to 2014.
Metcash cancels the dividend
We've been warning about Metcash's dividend since 2012. After last year's cut, today it was cancelled altogether.
Balancing Brickworks and Soul Patts
For a long time there's been little difference between Brickworks and Soul Patts. Now, a clear favourite has emerged.
Ainsworth forecasts lower sales
Despite now forecasting a 2% fall in revenue, Ainsworth expects 2015 profit to be similar to 2014.
IOOF sells Perennial thorn
This platform administrator and financial adviser has sold part of its underperforming funds management business.
Doubling down on Virtus and Monash IVF
Virtus and Monash face pricing pressure and a loss of market share, but you're being well compensated for those risks.
Virtus warns on growth
Virtus has lost market share in its key state, but there's still a lot to like about the IVF provider.
Gentrack: Interim result 2015
The billing software maker may miss its prospectus forecasts, but it's not all bad news.
DWS buys Symplicit
The loss of a contract will cost IT services company DWS about 4% of its revenue, but a new acquisition will more than make up the difference.
The ups and downs of South32
With South32's share price whipping around, Gaurav Sodhi looks at the best assets of the new miner.
Time to wager on Crown
Concerns over capital expenditure requirements and the impact of a Chinese corruption crackdown have created an opportunity in this casino icon.
Aristocrat: Interim result 2015
After completing its acquisition of VGT, this pokie maker is firing on all cylinders.
OzForex: Result 2015
This international payments business is winning new clients - but it's having to pay heavily for them.
Is Magellan's growth slowing?
An outflow of institutional funds has raised concerns that Magellan's growth may be stalling - but there are better reasons to be worried.
Cashing in on Amalgamated
After producing returns over the last two years that a growth investor would be pleased with, is it time to sell Amalgamated?
Call 1300 880 160
Start a chat
Schedule a call
